Sapphira Mazaya Salsabila, . (2022) PENGARUH PENGGUNAAN ANTIKOAGULAN TERHADAP MORTALITAS PASIEN COVID-19 DENGAN RISIKO KOAGULOPATI: Systematic Review. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
Text
ABSTRAK.pdf Download (36kB) |
|
Text
AWAL.pdf Download (404kB) |
|
Text
BAB 1.pdf Download (110kB) |
|
Text
BAB 2.pdf Restricted to Repository UPNVJ Only Download (322kB) |
|
Text
BAB 3.pdf Restricted to Repository UPNVJ Only Download (213kB) |
|
Text
BAB 4.pdf Restricted to Repository UPNVJ Only Download (357kB) |
|
Text
BAB 5.pdf Download (95kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (185kB) |
|
Text
DAFTAR RIWAYAT HIDUP.pdf Restricted to Repository UPNVJ Only Download (102kB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (1MB) |
|
Text
Hasil Plagiarisme.pdf Restricted to Repository staff only Download (10MB) |
|
Text
ARTIKEL KI.pdf Restricted to Repository staff only Download (408kB) |
Abstract
Background: One of the most common cause of death in hospitalized COVID-19 patients is related with the progression of coagulopathy that caused by hyperinflammatory events thus causing a systemic cytokine storm resulting systemic inflammatory response syndrome (SIRS). In COVID-19 guideline of treatment by Indonesian Association of Pulmonary, Cardiovascular, and Internal Medicine Physicians recommends the use of anticoagulants in all hospitalized COVID-19 patient adjusted with appropriate clinical judgement. This systematic review was conducted to analyze the effect of anticoagulants use on mortality in COVID-19 patients who at risk of coagulopathy. Methods: A systematic review conducted by starting a literature search from May to July 2021. The literature that being analyzed was from Google Scholar, PubMed, EBSCO, and Science Direct database using PRISMA-P 2020. Results: Datas were obtained from nine journals. Eight of them stated that the use of prophylactic and therapeutic doses, has an effect on reducing the mortality rate of COVID-19 patients and one journal did not see a significant difference on mortality of COVID-19 patients. Types of anticoagulant that are widely used in nine journals are heparin and fondaparinux with doses adjusted to coagulation marker. Conclusion:The use of anticoagulant is beneficial in reducing mortality rates in hospitalized COVID-19 patients.
Item Type: | Thesis (Skripsi) |
---|---|
Additional Information: | [No. Panggil: 1810211048] [Pembimbing 1: Hany Yusmaini] [Pembimbing 2: Feda Anisah Makiyah] [Penguji 1: Mila Citrawati] |
Uncontrolled Keywords: | Anticoagulant, coagulopathy, COVID-19, mortality |
Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
Divisions: | Fakultas Kedokteran > Program Studi Kedokteran (S1) |
Depositing User: | Sapphira Mazaya Salsabila |
Date Deposited: | 11 Feb 2022 06:36 |
Last Modified: | 11 Feb 2022 06:36 |
URI: | http://repository.upnvj.ac.id/id/eprint/16307 |
Actions (login required)
View Item |